Annexon Inc (ANNX)

$2.29

-0.08

(-3.38%)▲

Market is closed - opens 7 PM, 29 Sep 2023

Insights on Annexon Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 82.7% return, outperforming this stock by 142.8%

Performance

  • $2.22
    $2.38
    $2.29
    downward going graph

    3.28%

    Downside

    Day's Volatility :6.93%

    Upside

    3.78%

    downward going graph
  • $2.07
    $7.65
    $2.29
    downward going graph

    9.61%

    Downside

    52 Weeks Volatility :72.94%

    Upside

    70.07%

    downward going graph

Returns

PeriodAnnexon IncSector (Health Care)Index (Russel 2000)
3 Months
-30.5%
-1.7%
0.0%
6 Months
-40.45%
1.3%
-0.1%
1 Year
-60.1%
5.1%
5.6%
3 Years
-88.84%
24.3%
17.6%

Highlights

Market Capitalization
154.9M
Book Value
$3.48
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.81
Wall Street Target Price
15.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-41.79%
Return On Equity TTM
-81.24%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-149.6M
Diluted Eps TTM
-1.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.0
EPS Estimate Next Year
-1.87
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.56

Analyst Recommendation

Buy
    78%Buy
    21%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Annexon Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
13
Hold
3
3
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 581.22%

Current $2.29
Target $15.60

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Annexon Inc
Annexon Inc
-19.39%
-40.45%
-60.1%
-88.84%
-88.84%
Moderna, Inc.
Moderna, Inc.
-12.64%
-32.32%
-15.78%
41.01%
434.62%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.2%
0.68%
20.34%
45.14%
111.19%
Novo Nordisk A/s
Novo Nordisk A/s
-3.66%
17.13%
82.69%
165.14%
293.9%
Seagen, Inc.
Seagen, Inc.
3.05%
4.69%
56.63%
11.31%
161.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.55%
11.62%
19.58%
30.6%
81.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Annexon Inc
Annexon Inc
NA
NA
NA
-2.0
-0.81
-0.42
0.0
3.48
Moderna, Inc.
Moderna, Inc.
34.67
34.67
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.3
43.3
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.94
26.94
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Annexon Inc
Annexon Inc
Buy
$154.9M
-88.84%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.3B
434.62%
34.67
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
111.19%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$410.6B
293.9%
43.3
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
161.89%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
81.41%
26.94
35.4%

Institutional Holdings

  • SATTER MANAGEMENT CO., L.P.

    13.25%

  • Bain Capital Life Sciences Investors, LLC

    10.71%

  • Redmile Group, LLC

    6.58%

  • Logos Global Management LP

    6.57%

  • BlackRock Inc

    6.54%

  • Federated Hermes Inc

    5.74%

Corporate Announcements

  • Annexon Inc Earnings

    Annexon Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).

Organization
Annexon Inc
Employees
77
CEO
Mr. Douglas Love J.D., Esq.
Industry
Health Technology

Discover More

FAQs